Unless a researcher owns stock in a company whose drug is being tested, telling potential research volunteers about an investigator’s financial interests is unlikely to affect their willingness to volunteer, a new study shows. But many research volunteers put less trust in clinical trial leaders with financial conflicts.
For the study, Jeremy Sugarman, M.D., M.P.H., M.A., professor at the Johns Hopkins Berman Institute of Bioethics and The Johns Hopkins School of Medicine and his colleagues at Duke University School of Medicine and Wake Forest Schools of Medicine and Law recruited 3,623 adults with asthma or diabetes from a national database of individuals who are willing to participate in internet-based research. Overall, the recruits, almost all white, were well educated and had middle to high income levels. They were located in all regions of the United States.
Most of the respondents indicated that the financial disclosure was less important to their decision about participating than such factors as potential risks and benefits, and the purpose of the research.